相关实验视频

Updated: Jun 4, 2025

Cholesterol Efflux Assay

Cholesterol Efflux Assay

Published on: March 6, 2012

导出外基因的miR-107向caveolin-1,通过调节肝胆胆胆固醇分泌途径,促进胆结石的进展

Xinxing Wang¹, Mingze Ma², Lichao Zhu³

¹Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province 250021, China.

Biochemical pharmacology

|December 26, 2024

概括

携带miR-107的外体通过破坏胆酸运输和胆固醇代谢,促进胆固醇胆结石的形成. 抑制miR-107有助于恢复肝脏平衡,并预防胆结石.

科学领域:

分子生物学分子生物学
胃肠病学胃肠病学
生物化学生化学

背景情况:

胆固醇胆结石疾病很普遍,影响生活质量.
外基因组及其微RNA (miRNA) 载荷与各种疾病过程有关.
了解胆结石形成的分子机制对于开发有效的治疗方法至关重要.

研究的目的:

为了研究外体衍生的miRNA在胆固醇胆结石形成中的作用.
阐明外体 miR-107 影响胆结石病变的分子机制.
为了确定胆结石疾病的潜在治疗点.

主要方法:

从患有胆结石的患者和健康的对照人群中分离出外体.
进行了外体miRNA表达特征分析.
一个由饮食引起的胆结石的小鼠模型被用来评估miR-107.7的功能.
双 luciferase 记者测定确定了 miR-107 的目标基因.
西方斑块,免疫组织化学和q-PCR评估了与脂质和胆酸运输相关的基因和蛋白质表达.
分析了胆汁成分和胆固醇和指数.

主要成果:

在胆结石患者中,外体miR-107显著上调.
在小鼠模型中,抑制miR-107降低了胆结石的形成.
MiR-107直接准并抑制了caveolin-1,这反过来影响了胆盐输出 (BSEP) 的功能.
miR-107抑制增加了BSEP和胆固醇7α-基酶 (CYP7A1) 的表达,这是胆酸和胆固醇代谢的关键调节者.
miR-107促进了脂质样本的改变,并增加了胆汁中的胆固醇和指数 (CSI).
抑制miR-107改善了肝脏胆固醇平衡和胆酸载体表达.

结论:

外基因源的miR-107促进胆固醇胆结石的进展.
MiR-107通过向caveolin-1来调节肝胆胆胆固醇分泌途径.
向外体miR-107可能代表胆固醇胆结石疾病的新疗法策略.

关键词:

卡维奥林 - 1 - 一个洞穴.胆固醇胆固醇胆固醇异构体是什么? 异构体是什么? 外构体是什么?胆囊胆囊胆囊胆囊胆结石胆结石是一种胆结石.风险因素风险因素风险因素治疗方法治疗方法在 miR-107 系统中,这是一个微型RNA.

更多相关视频

Isolation and Profiling of MicroRNA-containing Exosomes from Human Bile

Isolation and Profiling of MicroRNA-containing Exosomes from Human Bile

Published on: June 13, 2016

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Preparation of Exosomes for siRNA Delivery to Cancer Cells

Published on: December 5, 2018

相关概念视频

Overview of Exosomes

Overview of Exosomes

Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...

Intralumenal Vesicles and Multivesicular Bodies

Intralumenal Vesicles and Multivesicular Bodies

Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

Maturation of Endosomes

Maturation of Endosomes

The early endosome containing internalized molecules matures through transformations in its location, morphology, intraluminal pH, and membrane protein composition. Together, these changes result in a more acidic late endosome that contains multiple intraluminal vesicles; therefore, the late endosome is also called a multivesicular body (MVB).
Changes in location
The maturing endosome moves along microtubules from the periphery of the cell towards the perinuclear region. This movement of the...